CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. It was also under development for the treatment of mycosis fungoides and recurrent or progressive malignant glioma. It is a combination of interferon alfa-2b with interferon gamma.
Let's personalize your content